Statins may reduce dementia risk in patients with type 2 diabetes

A long-term study involving over 132,000 individuals in Denmark suggests that statin use is associated with a reduced risk of dementia, particularly in patients with type 2 diabetes. Research presented at the European Society of Cardiology annual congress and published in The Lancet Regional Health Europe indicates that timing of treatment is a critical factor.

Patients who began statin therapy within the first year of their type 2 diabetes diagnosis showed a 15% lower likelihood of developing dementia compared to non-users. Those who initiated treatment later, within five years of diagnosis, saw a 10% reduction in risk. Researchers believe the drugs may protect brain health by lowering low-density lipoprotein (LDL) cholesterol, which prevents the narrowing or hardening of blood vessels that supply the brain.

While the study demonstrates a strong association, experts note that further research is required to establish direct causation. The findings align with broader medical recommendations identifying high cholesterol as a modifiable risk factor that could help prevent or delay approximately 45% of dementia cases. The widespread availability and affordability of statins make these findings significant for potential public health strategies.